"Aza Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic chemicals where carbon atoms have been replaced by nitrogen atoms.
| Descriptor ID |
D001372
|
| MeSH Number(s) |
D02.145
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aza Compounds".
Below are MeSH descriptors whose meaning is more specific than "Aza Compounds".
This graph shows the total number of publications written about "Aza Compounds" by people in this website by year, and whether "Aza Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aza Compounds" by people in Profiles.
-
A Novel Aza-MBP Altered Peptide Ligand for the Treatment of Experimental Autoimmune Encephalomyelitis. Mol Neurobiol. 2018 01; 55(1):267-275.
-
Electron shuttle-stimulated RDX mineralization and biological production of 4-nitro-2,4-diazabutanal (NDAB) in RDX-contaminated aquifer material. Biodegradation. 2010 Nov; 21(6):923-37.
-
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009 Aug 01; 180(3):273-80.
-
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother. 2008 Nov; 52(11):4037-42.
-
A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Pharmacotherapy. 2003 Jul; 23(7):925-32.
-
Utility of azapeptides as major histocompatibility complex class II protein ligands for T-cell activation. J Med Chem. 2001 Oct 25; 44(22):3700-9.